^
Association details:
Biomarker:No biomarker
Cancer:Kidney Cancer
Drug:Bavencio (avelumab) (PD-L1 inhibitor) +
Inlyta (axitinib) (VEGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Kidney Cancer: Principles for systemic therapy for relapse or stage IV disease...Other Recommended Regimens...Axitinib + avelumab